A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Bolt Biotherapeutics, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 294,039 shares of BOLT stock, worth $149,959. This represents 0.0% of its overall portfolio holdings.

Number of Shares
294,039
Previous 276,739 6.25%
Holding current value
$149,959
Previous $207,000 7.73%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$0.58 - $0.75 $10,034 - $12,975
17,300 Added 6.25%
294,039 $191,000
Q2 2024

Aug 09, 2024

SELL
$0.73 - $1.5 $175,855 - $361,347
-240,898 Reduced 46.54%
276,739 $207,000
Q1 2024

May 13, 2024

BUY
$1.01 - $1.4 $73,087 - $101,309
72,364 Added 16.25%
517,637 $725,000
Q4 2023

Feb 13, 2024

BUY
$0.85 - $1.12 $111,421 - $146,814
131,084 Added 41.72%
445,273 $499,000
Q3 2023

Nov 14, 2023

SELL
$0.98 - $1.46 $166,355 - $247,835
-169,750 Reduced 35.08%
314,189 $327,000
Q2 2023

Aug 11, 2023

BUY
$1.27 - $1.95 $34,544 - $53,040
27,200 Added 5.96%
483,939 $619,000
Q1 2023

May 12, 2023

BUY
$1.29 - $1.66 $19,608 - $25,232
15,200 Added 3.44%
456,739 $635,000
Q4 2022

Feb 13, 2023

BUY
$1.26 - $1.51 $60,078 - $71,998
47,681 Added 12.11%
441,539 $574,000
Q3 2022

Nov 14, 2022

SELL
$1.48 - $2.61 $214,178 - $377,706
-144,715 Reduced 26.87%
393,858 $583,000
Q2 2022

Aug 12, 2022

BUY
$1.41 - $2.91 $350,346 - $723,056
248,473 Added 85.65%
538,573 $1.1 Million
Q1 2022

May 13, 2022

BUY
$2.74 - $4.82 $551,288 - $969,784
201,200 Added 226.32%
290,100 $795,000
Q4 2021

Feb 11, 2022

BUY
$4.19 - $13.97 $40,224 - $134,112
9,600 Added 12.11%
88,900 $436,000
Q3 2021

Nov 12, 2021

BUY
$11.15 - $18.6 $209,954 - $350,238
18,830 Added 31.14%
79,300 $1 Million
Q2 2021

Aug 13, 2021

BUY
$15.4 - $31.46 $931,238 - $1.9 Million
60,470 New
60,470 $935,000

Others Institutions Holding BOLT

About Bolt Biotherapeutics, Inc.


  • Ticker BOLT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 37,641,500
  • Market Cap $19.2M
  • Description
  • Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-e...
More about BOLT
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.